BEACON-IPF for the treatment of idiopathic pulmonary fibrosis

The study is for people who: Are 40 years of age or older at screening. Have a current diagnosis of IPF (within 7 years prior to screening). The study will examine whether bexotegrast can slow down or halt the progression of IPF by reducing scar formation (fibrosis) in participants over the study period. The study will also assess what effects bexotegrast has on participants’ lung function. Your participation in the study will last for approximately one year.